Related Experiment Video

Updated: Apr 7, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.3K

[eIF3a gene polymorphism and chemo-sensitivity to platinum-based drugs in ovarian cancer]

Caiyi Zhang1, Shufen Zhang1, Yingzi Liu2

  • 1Department of Gynaecology and Obstetrics,Xiangya Hospital,Central South University, Changsha 410008, China.

Zhong Nan Da Xue Xue Bao. Yi Xue Ban = Journal of Central South University. Medical Sciences
|July 13, 2015
PubMed
Abstract

Insights

Investigating eukaryotic initiation factor 3a (eIF3a) polymorphisms in ovarian cancer revealed no significant impact on chemotherapy response. These eIF3a gene variations do not appear to influence chemo-sensitivity to platinum-based drugs.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacogenomics

Background:

  • Ovarian cancer remains a leading cause of cancer-related mortality in women.
  • Platinum-based chemotherapy is a cornerstone treatment, but response varies significantly among patients.
  • Identifying genetic markers to predict chemo-sensitivity is crucial for personalized treatment strategies.

Purpose of the Study:

  • To explore the association between specific polymorphisms in the eukaryotic initiation factor 3a (eIF3a) gene and the chemo-sensitivity of ovarian cancer to platinum-based drugs.
  • To analyze the genotypic frequencies of eIF3a polymorphisms (rs3824830, rs77382849, rs10787899, and rs3740556) in ovarian cancer patients undergoing chemotherapy.

Main Methods:

  • Genotyping of 57 ovarian cancer cases was performed using Matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS).
  • Analysis focused on four eIF3a polymorphic sites: rs3824830, rs77382849, rs10787899, and rs3740556.
  • Statistical analysis investigated the relationship between genotypes and response to platinum-based chemotherapy up to 6 cycles.

Main Results:

  • Genotype distributions for eIF3a rs3824830, rs77382849, and rs10787899 were determined. No mutations were found in eIF3a rs3740556.
  • Initial analysis suggested potential associations between eIF3a rs10787899 genotypes (GA and AA) and resistance to platinum drugs, with increased odds ratios.
  • However, after adjusting for age and FIGO stage, these associations were no longer statistically significant (P>0.05).

Conclusions:

  • The investigated polymorphisms in the eIF3a gene (rs3824830, rs77382849, and rs10787899) do not significantly impact the chemo-sensitivity of ovarian cancer to platinum-based chemotherapy.
  • No mutations were observed in the eIF3a rs3740556 locus.
  • These findings suggest that eIF3a polymorphisms are not reliable predictors of response to platinum-based chemotherapy in ovarian cancer.

More Related Videos

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K
Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

2.4K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
116
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
69